TrialAmerican journal of clinical dermatology2024
Early and Sustained Improvements in Symptoms and Quality of Life with Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: 52-Week Results from Two Phase III Randomized Clinical Trials (Measure Up 1 and Measure Up 2).
Jonathan I Silverberg et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
24 papers cite it
this papertrialcites it